| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,472,742 | 10 | 100 |
| Degnan Chris | Chief Financial Officer | 0 | $0 | 1 | $80,791 | $-80,791 |
| Smith Jason Drew | General Counsel | 0 | $0 | 2 | $211,880 | $-211,880 |
| Schoenberg Mark | Chief Medical Officer | 0 | $0 | 7 | $4.18M | $-4.18M |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for …
Over the last 12 months, insiders at UroGen Pharma Ltd. have bought $0 and sold $4.47M worth of UroGen Pharma Ltd. stock.
On average, over the past 5 years, insiders at UroGen Pharma Ltd. have bought $2,096 and sold $1.28M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 160 shares for transaction amount of $2,096 was made by Schoenberg Mark (Chief Medical Officer) on 2021‑11‑18.
| 2026-10-08 | Sale | Degnan Chris | Chief Financial Officer | 2,202 0.0045% | $36.69 | $80,791 | -6.64% | |
| 2026-09-08 | Sale | Schoenberg Mark | Chief Medical Officer | 871 0.0017% | $42.92 | $37,383 | -7.58% | |
| 2026-09-08 | Sale | Smith Jason Drew | General Counsel | 1,519 0.0029% | $42.54 | $64,618 | -7.58% | |
| 2026-08-20 | Sale | Schoenberg Mark | Chief Medical Officer | 60,677 0.1211% | $47.05 | $2.85M | -11.59% | |
| 2026-07-09 | Sale | Schoenberg Mark | Chief Medical Officer | 10,000 0.0204% | $40.00 | $400,000 | +2.95% | |
| 2026-06-22 | Sale | Schoenberg Mark | Chief Medical Officer | 10,000 0.0205% | $35.01 | $350,100 | +16.99% | |
| 2026-06-08 | Sale | Schoenberg Mark | Chief Medical Officer | 5,222 0.0107% | $27.30 | $142,561 | +48.81% | |
| 2026-02-03 | Sale | Schoenberg Mark | Chief Medical Officer | 7,373 0.0155% | $19.69 | $145,174 | +67.40% | |
| 2026-02-03 | Sale | Smith Jason Drew | General Counsel | 7,479 0.0157% | $19.69 | $147,262 | +67.40% | |
| 2025-11-19 | Sale | Schoenberg Mark | Chief Medical Officer | 10,000 0.0211% | $25.00 | $250,000 | +11.32% | |
| 2025-10-08 | Sale | Degnan Chris | Chief Financial Officer | 2,203 0.0046% | $16.85 | $37,121 | +39.12% | |
| 2025-09-08 | Sale | Schoenberg Mark | Chief Medical Officer | 871 0.0017% | $19.11 | $16,645 | +7.98% | |
| 2025-09-08 | Sale | Smith Jason Drew | General Counsel | 1,520 0.0029% | $19.11 | $29,047 | +7.98% | |
| 2025-08-11 | Sale | Schoenberg Mark | Chief Medical Officer | 10,000 0.021% | $17.69 | $176,900 | +19.52% | |
| 2025-07-28 | Sale | Schoenberg Mark | Chief Medical Officer | 5,149 0.0113% | $19.14 | $98,552 | +12.80% | |
| 2025-07-28 | Sale | Smith Jason Drew | General Counsel | 7,522 0.0165% | $19.14 | $143,971 | +12.80% | |
| 2025-06-09 | Sale | Schoenberg Mark | Chief Medical Officer | 5,162 0.0118% | $7.37 | $38,044 | +183.62% | |
| 2025-01-31 | Sale | Schoenberg Mark | Chief Medical Officer | 4,551 0.0106% | $11.14 | $50,698 | +54.95% | |
| 2025-01-31 | Sale | Smith Jason Drew | General Counsel | 7,379 0.0172% | $11.14 | $82,202 | +54.95% | |
| 2024-09-09 | Sale | Schoenberg Mark | Chief Medical Officer | 859 0.002% | $13.08 | $11,236 | -12.81% |
| Schoenberg Mark | Chief Medical Officer | 59882 0.1225% | $2.06M | 3 | 40 | <0.0001% |
| Smith Jason Drew | General Counsel | 53141 0.1087% | $1.83M | 1 | 13 | <0.0001% |
| Barrett Elizabeth A. | Chief Executive Officer | 300985 0.6158% | $10.35M | 4 | 2 | <0.0001% |
| Henderson Molly | Chief Financial Officer | 5248 0.0107% | $180,531.20 | 1 | 2 | <0.0001% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$607,395,062 | 99 | 4.23% | $1.88B | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$61,893,001 | 38 | 19.63% | $1.89B | |
$530,111,731 | 35 | 8.69% | $1.51B |
| Increased Positions | 82 | +43.16% | 9M | +20.3% |
| Decreased Positions | 79 | -41.58% | 9M | -21.41% |
| New Positions | 31 | New | 5M | New |
| Sold Out Positions | 27 | Sold Out | 5M | Sold Out |
| Total Postitions | 193 | +1.58% | 44M | -1.11% |
| Rtw Investments, Lp | $99,057.00 | 9.67% | 4.54M | 0 | 0% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $91,911.00 | 8.97% | 4.22M | +4M | New | 2025-09-30 |
| Toronto Dominion Bank | $69,553.00 | 6.79% | 3.19M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $56,272.00 | 5.49% | 2.58M | +176,045 | +7.32% | 2025-09-30 |
| Morgan Stanley | $55,120.00 | 5.38% | 2.53M | +49,976 | +2.02% | 2025-09-30 |
| Jefferies Financial Group Inc. | $47,952.00 | 4.68% | 2.2M | 0 | 0% | 2025-09-30 |
| Silverarc Capital Management, Llc | $34,385.00 | 3.36% | 1.58M | -445,199 | -22.01% | 2025-09-30 |
| Millennium Management Llc | $32,018.00 | 3.13% | 1.47M | +874,706 | +147.25% | 2025-09-30 |
| Acorn Capital Advisors, Llc | $27,463.00 | 2.68% | 1.26M | 0 | 0% | 2025-09-30 |
| Sg Americas Securities, Llc | $25,231.00 | 2.46% | 1.16M | +8,302 | +0.72% | 2025-09-30 |